Citigroup Boosts Price Target on Allergan (AGN)

On Thursday analysts at Citigroup increased the price target on healthcare company Allergan, Inc. (AGN) citing continuous double digit growth in its core businesses.

The analysts back a “Buy” rating on AGN and now see shares reaching $124. This target suggests a 14% upside to Wednesday’s closing price of $108.53.

Allergan shares were down $1.44, or -1.36%, during morning trading on Thursday. The stock is up about 23% over the past year.

The Bottom Line
Shares of Allergan (AGN) have a dividend yield of 0.19% based on Thursday’s intraday trading price of $107.37 and the company’s annualized dividend payout of 20 cents per share.

Allergan, Inc. (AGN) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here